Prostate Cell News Volume 14.27 | Jul 21 2023

    0
    14








    2023-07-21 | PCN 14.27


    Prostate Cell News by STEMCELL Technologies
    Vol. 14.27 – 21 July, 2023
    TOP STORY

    Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity, and AR-Targeted Therapy Resistance in Prostate Cancer

    The authors identified synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP) as an endogenous molecular brake that suppressed APOBEC-driven mutagenesis in prostate cancer.
    [Cancer Cell]

    Full ArticleGraphical Abstract
    Enjoy your weekend. Your cells will too. Reduce medium acidosis with mTeSRâ„¢ Plus.
    PUBLICATIONSRanked by the impact factor of the journal

    A lncRNA from the FTO Locus Acts as a Suppressor of the m6A Writer Complex and p53 Tumor Suppression Signaling

    Researchers demonstrated that FTO-IT1 long noncoding RNA (lncRNA) was upregulated and positively correlated with poor survival of patients with wild-type p53-expressing prostate cancer.
    [Molecular Cell]

    Full ArticleGraphical Abstract

    Circulating Trans Fatty Acids Are Associated with Prostate Cancer in Ghanaian and American Men

    Scientists analyzed 24 circulating fatty acids in 2934 men, including 1431 prostate cancer cases and 1503 population controls from Ghana and the United States, using CLIA-certified mass spectrometry-based assays.
    [Nature Communications]

    Full Article

    Spermine Is a Natural Suppressor of AR Signaling in Castration-Resistant Prostate Cancer

    Investigators showed that spermine inhibited full-length androgen receptor (AR) and androgen receptor splice variant 7 signaling and suppressed castration-resistant prostate cancer cell proliferation by directly binding and inhibiting protein arginine methyltransferase protein arginine methyltransferases (PRMT) 1.
    [Cell Reports]

    Full ArticleGraphical Abstract

    LSD1 Promotes Prostate Cancer Cell Reprogramming by Repressing TP53 Signaling Independently of Its Demethylase Function

    Scientists determined that lysine-specific demethylase 1 (LSD1) was highly upregulated in neuroendocrine prostate cancer (NEPC) vs. adenocarcinoma patient tumors. LSD1 suppression with RNAi or allosteric LSD1 inhibitors—but not catalytic inhibitors—reduced NEPC cell survival.
    [JCI Insight]

    AbstractGraphical Abstract

    Influence of ADT on B7-H3 Expression during CRPC Progression from Hormone-Naïve Prostate Cancer

    The authors performed a longitudinal study using their unique prostate cancer patient-derived xenograft models and assessed B7-H3 expression during post-androgen deprivation therapy (ADT) disease progression.
    [Cancer Gene Therapy]

    Full Article

    Switching Mechanism from AR to EGFR Signaling via 3-O-Sulfated Heparan Sulfate in Castration-Resistant Prostate Cancer

    Using the human prostate cancer cell line C4-2, investigators found that epidermal growth factor (EGF)-activated EGFR–ERK1/2 signaling via 3-O-sulfated heparan sulfate produced by HS 3-O-sulfotransferase 1 is activated in C4-2 cells under hormone depletion.
    [Scientific Reports]

    Full Article

    Microfluidic-Based Prostate Cancer Model for Investigating the Secretion of Prostate-Specific Antigen and microRNAs In Vitro

    Researchers developed a microphysiological system model comprising conventional prostate cancer cells to evaluate their activity under dynamic culture conditions. Androgen-sensitive and androgen-insensitive cells were grown in conventional and 3D cultures, both static and dynamic.
    [Scientific Reports]

    Full Article

    METTL3-Mediated m6A Modification of Pri-miR-148a-3p Affects Prostate Cancer Progression by Regulating TXNIP

    Methyltransferase-like 3 (METTL3), miR-148a-3p, and thioredoxin interacting protein (TXNIP) levels were determined using RT-qPCR and Western blotting. The m6A modification level of miR-148a-3p was observed by Me-RIP assay.
    [Environmental Toxicology]

    Abstract
    Explore this validated protocol for the gene-editing of Human CD34+ Hematopoietic Stem and Progenitor Cells using the ArciTectâ„¢ CRISPR-Cas9 System.
    REVIEWS

    Engineering Prostate Cancer In Vitro: What Does It Take?

    Scientists highlight the current in vitro 3D prostate cancer (PCa) models with a special focus on organoids and discuss engineering approaches to create more physiologically relevant PCa organoid models.
    [Oncogene]

    Full Article

    The Diagnosis and Treatment of Castrate-Sensitive Oligometastatic Prostate Cancer: A Review

    The authors summarize the definition and classification of oligometastatic prostate cancer, assess the diagnostic methods and imaging modalities utilized, and review the treatment options and outcomes.
    [Prostate Cancer and Prostatic Diseases]

    Abstract
    INDUSTRY AND POLICY NEWS

    FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Ambrx Biopharma Inc. announced that the U.S. FDA has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer.
    [Ambrx Biopharma Inc.]

    Press Release
    FEATURED EVENT

    AFLAS Congress 2023

    September 13 – 15, 2023
    Seogwipo, South Korea

    > See All Events

    JOB OPPORTUNITIES

    Applied Research Scientist – Language and Intelligence Laboratory

    Moffitt Cancer Center – Tampa, Florida, United States

    Senior Scientist – Oncology

    Washington University – St. Louis, Missouri, United States

    Postdoctoral Positions – Cancer Drug Persistence & Tumor Microenvironment

    Albert Einstein College of Medicine – New York City, New York, United States

    Scientist – Urology

    University of Miami – Miami, Florida, United States

    Scientific Director – Clinical Research

    NCI Center for Cancer Research – Bethesda, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter